Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue 2, 2008, Pages 110-117

  Moosmann, Nicolas ^a   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Capecitabine; Epidermal growth factor receptor; Irinotecan; Leucovorin; Oxaliplatin

Indexed keywords

ANTIDIARRHEAL AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CELECOXIB; CETUXIMAB; EMOLLIENT AGENT; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; IFL PROTOCOL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ALOPECIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INTOXICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; IMMUNOTHERAPY; ISCHEMIA; LETHARGY; METASTASIS; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; RASH; REPEATED DRUG DOSE; REVIEW; STOMATITIS; THROMBOEMBOLISM; VOMITING; CANCER STAGING; COLORECTAL TUMOR; DRUG EFFECT; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84912147127     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/ccc.2008.n.015     Document Type: Review

References (55)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
3. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-8.
4. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22:3766-75.
5. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7.
6. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
7. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
8. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
9. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-92.
10. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-106.
11. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
12. Wilke H, Glynne-Jones R, Thaler J, et al. MABEL - a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. J Clin Oncol 2006; 24(18 suppl):158s (Abstract 3549).
13. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial. J Clin Oncol 2007; 25(18 suppl):164s (Abstract 4000).
14. Ducreux M, Bennouna J, Hebbar M, et al. Efficacy and safety findings from a randomized phase III study of capecitabine plus oxaliplatin (XELOX) versus infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) for metastatic colorectal cancer. J Clin Oncol 2007; 25(18 suppl):170s (Abstract 4029).
15. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol 2007; 25(18 suppl):171s (Abstract 4030).
16. Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al. Phase III study of capecitabine plus oxaliplatin versus continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial. J Clin Oncol 2007; 25:4224-30.
17. Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25:4217-23.
18. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20:1759-66.
19. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:2084-91.
20. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs. capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer. Proc Am Soc Clin Oncol 2003; 22:255 (Abstract 1022).
21. Shields AF, Zalupski MM, Marshall JL, et al. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 2004; 100:531-7.
22. Zeuli M, Nardoni C, Pino MS, et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003; 14:1378-82.
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
24. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697-705.
25. Borner MM, Bernhard J, Dietrich D, et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005; 16:282-8.
26. Bajetta E, Di Bartolomeo M, Mariani L, et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100:279-87.
27. Cartwright T, Lopez T, Vukelja SJ, et al. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 2005; 5:50-6.
28. Patt Y, Lin E, Liebman J, et al. Capecitabine plus irinotecan: a highly active first-line treatment for metastatic colorectal cancer. Presented at: the 2004 ASCO Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract 228.
29. Rea DW, Nortier JW, Ten Bokkel Huinink WW, et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 2005; 16:1123-32.
30. de Greve J, Koehne C, J. H, et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first-line treatment of metastatic colorectal cancer. Long-term results of the prospective multicenter EORTC phase III study 40015. J Clin Oncol 2006; 24(18 suppl):165s (Abstract 3577).
31. Fuchs C, Marshall J, Mitchell E, et al. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). J Clin Oncol 2006; 24(18 suppl):147s (Abstract 3506).
32. Punt CJ, Koopman M, Douma J, et al. Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer: A Dutch Colorectal Cancer Group (DCCG) phase III study. J Clin Oncol 2007; 25(18 suppl):166s (Abstract 4012).
33. Kohne C, de Greve J, Bokemeyer C, et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first-line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORT phase III study 40015. J Clin Oncol 2005; 23(16 suppl):252s (Abstract 3525).
34. Koopman M, Antonini NF, Douma J, et al. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. Ann Oncol 2006; 17:1523-8.
35. Kohne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986. J Clin Oncol 2005; 23:4856-65.
36. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19:32S-40S.
37. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172-87.
38. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-99.
39. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(suppl 4):S9-15.
40. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1:1311-8.
41. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5-FU/LV (FOLHRI) or oxaliplatin/5-FU/LV (FOLFOX) +/- cetuximab (C225) for patients (pts) with untreated metastatic adeno carcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results. J Clin Oncol 2006; 24(18 suppl):148s (Abstract 3509).
42. Dittrich C, Hoehler T, Lordick F, et al. A phase I/II study of cetuximab in combination with 5-fluorouracil/folinic acid plus weekly oxaliplatin (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR). Preliminary results. Presented at: the World Congress on Gastrointestinal Cancer; June 28-July 1, 2006; Barcelona, Spain. Abstract O-019.
43. Dakhil S, Cosgriff T, Headley D, Boccia R, Badarinath S. Cetuximab plus FOLFOX6 as first-line therapy for metastatic colorectal cancer (an International Oncology Network study, I-03-002). J Clin Oncol 2006; 24(18 suppl):160s (Abstract 3557).
44. Colucci G, Giuliani F, Mattioli R, et al. FOLFOX-4 plus cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). J Clin Oncol 2006; 24(18 suppl):160s (Abstract 3559).
45. Andre T, Tabernero J, Van Cutsem E, et al. Phase II study with cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor receptor-expressing metastatic colorectal cancer: final results. Presented at: the 2007 ASCO Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 334.
46. Borner M, Mingrone W, Koeberle D, et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer: A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2006; 24(18 suppl):158s (Abstract 3551).
47. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer: OPUS, a randomized phase II study. J Clin Oncol 2007; 25(18 suppl):172s (Abstract 4035).
48. Heinemann V, Fischer von Weikersthal L, Moosmann N, et al. Cetuximab plus capecitabine plus irinotecan versus cetuximab plus capecitabine plus oxaliplatin as first-line therapy for patients with metastatic colorectal cancer: Preliminary results of a randomized phase II trial of the AIO study group. J Clin Oncol 2006; 24(18 suppl):158s (Abstract 3550).
49. Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5-FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 21:135a (Abstract 536).
50. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17:450-6.
51. Peeters M, Raoul J, Van Laethem J, et al. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). Presented at: the 2005 European Cancer Conference; October 30-Noveber 3, 2005; Paris, France. Abstract 664.
52. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14(suppl 2):ii13-6.
53. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240:644-57; discussion 657-8.
54. Maughan T, on behalf of the COIN Trial Management Group and Investigators. Cetuximab, oxaliplatin and fluoropyrimidine: Toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR10) trial. J Clin Oncol 2007; 25(18 suppl):181s (Abstract 4070).
55. Diaz-Rubio E, Tabernero J, Van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): An international phase II study. J Clin Oncol 2005; 23(16 suppl):254s (Abstract 3535).